Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance ...

Acne vulgaris is the most common skin condition in the United States, affecting an estimated 50 million people annually1.

Potential Positives Denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial, demonstrating its efficacy for the treatment of moderate to severe acne vulgaris.

Acne vulgaris is a multifactorial skin disorder marked by inflammatory and non-inflammatory lesions that can cause significant physical and psychological distress. Traditional treatment options ...

“FASN inhibition represents a novel potential approach to treat moderate to severe acne vulgaris, a widespread condition impacting more than 640 million people worldwide.

DelveInsight’s report, “Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive overview of Acne Vulgaris, including historical and projected epidemiology as ...

Clinical Pearls Isoretinoin is an effective treatment for moderate to severe acne. Nonetheless, rates of recurrent acne after treatment may exceed 40%. In the current study of patients with cystic ...

About Acne vulgaris Acne vulgaris is the most common skin condition in the United States, affecting an estimated 50 million people annually1.

Acne vulgaris is the most common skin condition in the United States, affecting an estimated 50 million people annually1.